> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-68/
- Published: 2022-03-27T12:00:00.000Z
- Updated: 2026-09-14T17:38:15.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5138688

**Thermo Fisher Scientific** has agreed to acquire **Patheon**, a pharmaceutical contract development and manufacturing organization, for $7.2 billion, which includes the assumption of about $2.0 billion in debt.

**WuXi AppTec** has completed its acquisition of **HD Biosciences**, a leading biology-focused preclinical drug discovery contract research organization. HD offers plate-based pharmacology and screening capability, “hit identification,” lead discovery, in vivo pharmacology and other related services.

**Biogen** has completed an asset purchase of **Remedy Pharmaceuticals**’ Phase 3 candidate, Cirara (intravenous glyburide), which is seeking an indication for treating large hemispheric infarction, a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality.

**Medtronic** has agreed to acquire an option on **QT Vascular**’s Chocolate PTA non-drug-coated balloon for treating peripheral vascular disease. The purchase price is $28 million.